I don’t. The way things are going, I’m really happy with this.

Something is going on, someone figured out something. Well, someone else.

Right, so looking at the trades today, you realize that for about 5 seconds, and only 5 seconds, the ticker dropped 84% from the previous close. Over transactions summing up to 67500 shares, at 0.0004, thus 27$. This is almost the inverse of the price spike that we saw after the DoD funding announcement. What should we conclude from this?

From a late 2023 news release, Ab Initio, an Australian will manufacture the lipid nanoparticles for The upcoming research, clinical trials, etc.

The Nanoparticles delivery system, which RespireRx has a patent on, and is the focus of the subsidiary in Australia, ResolutionRx. From their documentation:

RSPI does not have IP on IDRA 21 and no one else does either, because of a technicality pertaining to its molecular structure. It’s not sold by a legitimate, FDA approved pharmaceuticals manufacturer. It may be sold by chemical reagents suppliers to university labs for research purposes, in which case it’s regulated, and characterized, and probably too expensive to be bought by ordinary individuals for personal consumption. It is traded in “grey markets”, as “dietary supplement” or “nootropic” as it’s not classified as an addictive drug that can be abused, or intoxicate people. Criminal drug dealers are not interested to peddle it, it does not make people high, and junkies aren’t interested.

Over in Canada I’ve been able to buy it 0.0003-0.0004, but only in small lots, no greater than 100000 such as the transaction fee was sometimes more than the value!

https://www.coherentmi.com/industry-reports/obstructive-sleep-apnea-osa-pipeline-market

Market report out in September 2024 mentioning RespireRX RSPI.

OBSTRUCTIVE SLEEP APNEA OSA PIPELINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

There is definitely a significant step up in peer-reviewed publications pertaining to positive allosteric modulators of ligand-gated ion channels in neurons. It used to be that even many neuroscientists were not much familiar with them, but now a lot of people are talking about them. Respirerx has patents covering many of them. In the case of the AMPA receptors, they basically own all of them, except for a few odd molecules like IDRA-21 which has been circulating in nootropics “research chemicals” grey markets online for a while. Probably because it’s relatively easy and cheap to synthesize.

So the good thing about all of this, is that inasmuch as it’s a compilation of mischief and basically sad, unfortunate events, it absolutely, and totally makes sense, and is completely consistent with all the information we’ve had so far. So thanks a lot! I am a little surprised to be reassured by this.

What’s happening with them, is that they are extremely carefully managing their freedom. They want to minimize stakeholders pressuring them to get this to go directions they want to avoid. To avoid rushing things and producing a half-baked turd. Maybe that was the reason why the Novint Falcon was a failure. They know how to spin this.

In the expert market if someone wants to buy this they know what they are doing, I guess, by definition. They really mean to acquire this. Like an auction at Christie’s. So the share price can take off in there, for most onlookers to just watch and drool. Hello everyone!! I get to keep my saliva in my head.

Sell at 019 first thing in the morning.

TrendTrade has become a black hole, he collapsed under his own weight down to a single point where the laws of physics cease to apply.

So they really don’t need to RS this at all. They set that up as an option, a flexibility. It would not be in their interest to RS this, they hardly raised any capital from retail at all.

If 6 millions shares trade on this ticket in a single day it’ll blow its top off. Too quick.

Even the market makers, or whatever you call them on the expert market, are sleeping on the switch here.

The ask moved up to 0.024

Today bids at 0.02 were filled. How long will this last?

Royal Bank of Canada Investing

If that’s the case it’s not the first time such a provision is put in place as incentive to restraint from messing with the share structure. Because that had clearly been a recurring concern that persistently undermined trust in the board of director. See my earlier comments on the influence (good!!!!) of the new appointee, Dr Dariusz Nasiek, who imposed some discipline (austerity?). I’m really glad he’s on board.

This is a good thing. That company is just too shiny and precious. They did not want to be traded in a better exchange too soon, it would have robbed them of the flexibility and freedom they needed to set things up correctly. So this is a very good indication for just how clever the new management team is.

This is an excellent document, absolutely gorgeous. It’s so well made it’s disgusting. Let me note the following. ::1. They have a clear, specified plan. ::2. They need to raise a very significant lump of capital. ::3. They singled out essentially ONE channel for investors. ::4. They deliberately exhausted the scope to dilute it.

So why would they RS this?

By the way, one trade on a Sunday at 11AM. 840,833 shares, on the expert market. Trading hours mean nothing in there. What do you make of that?

That’s what I meant when I described them as pharma diva queens. Some part of them anyway. Complacency. Their livelihood does not hinge on this IP, but neither will they let it go for a song, or give it up/pass it on to other things.

There is an emerging awareness of the usefulness of dementia drugs for ADHD, and vice versa. For instance, memantine, an NMDA antagonist. That’s because the AMPA receptor and the NMDA receptor are specifically activated simultaneously in most forms of synaptic plasticity. Plasticity regulates learning on longer timescales, attention on shorter timescales.

RespireRx Pharmaceuticals company profile
Therapies for obstructive sleep apnea and brain-mediated breathing disorders
1987•Glen Rock (United States)•Public
share
Last updated: August 24, 2024

So the nature of the uncertainty is about whether going to the EM was intentional. If it really is not so, then what happening is hard to make sense of. If it is then something huge is brewing, and they, or some third parties sought to minimize interference. A sandbox.

But if there are none reported, it doesn’t mean none happened. It means they have to get to it. Lot’s of elbow room.

Would it really surprise you if that was the case? There must be many ways to do so as well.

I could not have said it better.

Even after going into the expert market the stock kept trading, and some of the price shifts were huge. But it traded, I even had buy orders filled for a few 100 thousand shares. There were some million share trades. But now this week trading all but ceased. So it’s either not reported, or it was halted. Probably no one with shares is willing to sell at all in the 000s. Maybe no buy orders in the 00s either, or there are shenanigans. And yet the science keeps coming out.

Purchased into this stock in 2009. It was not RSPI back then, and as an investment it disappointed many, because there was so much promise. Then those few Cortex stocks I had made babies, and I just kept accumulating them, steady. Sooner or later something will hit the AMPA receptors.

That happens sometimes when you have too many tabs open in the browser.

CX516, ampalex, is not in the pipeline because CX717 is superior in essentially every way, but it remains in use in primary research labs as a standard for comparison in experimental assays. It is also a lot cheaper for those university lab budgets!

https://en.wikipedia.org/wiki/CX-516

Sorry, wrong board!

CX516, ampalex, is not in the pipeline because CX717 is superior in essentially every way, but it remains in use in primary research labs as a standard for comparison in experimental assays. It is also a lot cheaper for those university lab budgets!

https://en.wikipedia.org/wiki/CX-516

A sober overview of the inherent challenges, and promises of developing pharmaceuticals modulating the AMPA receptor. Respirerx RSPI holds patents for most medical uses of these molecules.

https://www.sciencedirect.com/science/article/abs/pii/S1359644621003536?via%3Dihub

That seems like a lot all in a rather short time. Is this indicative of a one-off?

So many eyes connected to really good brains, observing. However really good brains often don’t have deep pockets. But brains with deep pockets tend to really like the really good brains of others.

Indeed, This is a clear, no-nonsense, peer-reviewed article, but it’s also totally a PR exercise, spinning all the right info to support the framing of CX717 into their pipeline. So timed, deliberate, an instrument for showing off legitimacy. So they’re not staging this, this is bona fide science.

Now someone who gets this can tell someone who can tell someone who can tell someone with a few million dollars to spare. Basically, this is a reflection of their mindset: this is what they perceive as showing off valuable stuff in the world. Okay, they may not know how to directly tickle deep pockets very well, but they’re earnest.